Denali Therapeutics

Yahoo Finance • 2 months ago

Denali therapeutics' Ho Carole sells $52k in stock

Denali Therapeutics Inc. (NASDAQ:DNLI), a $2.1 billion market cap biotech company currently trading at $14.46, saw its Chief Medical Officer Carole Ho sell 3,743 shares of common stock on August 12 and 13, 2025, for approximately $51,683.... Full story

Yahoo Finance • 2 months ago

Denali Therapeutics COFO Schuth sells $39884 in stock

Alexander O. Schuth, Chief Financial Officer and Secretary of Denali Therapeutics Inc. (NASDAQ:DNLI), sold 2,937 shares of the company’s common stock on August 12, 2025. The shares were sold at a weighted average price ranging from $13.35... Full story

Yahoo Finance • 2 months ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path for Sanfilippo syndrome Type A aligned... Full story

Yahoo Finance • 3 months ago

William Blair reiterates Outperform rating on Denali stock after BLA acceptance

Investing.com - William Blair has reiterated its Outperform rating on Denali Therapeutics Inc. (NASDAQ:DNLI) following the Biologics License Application (BLA) acceptance and priority review for the company’s Hunter syndrome treatment. Th... Full story

Yahoo Finance • 5 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “The completion of our... Full story

Yahoo Finance • 6 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026Alignment through recent interactions with CDER on path to accelerated approval and conversion t... Full story

Yahoo Finance • 7 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. “In 2024,... Full story

Yahoo Finance • 8 months ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behavior Long-term safety data with median follow-u... Full story

Yahoo Finance • 2 years ago

Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results

Net Loss: Reported a net loss of $119.5 million for Q4 and $145.2 million for the full year 2023. Collaboration Revenue: No collaboration revenue for Q4 2023, but a significant increase to $330.5 million for the full year. Research and Dev... Full story

Yahoo Finance • 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Denali Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-... Full story

Yahoo Finance • 2 years ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Denali Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-... Full story

Yahoo Finance • 2 years ago

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Bu... Full story

Yahoo Finance • 2 years ago

After losing 39% in the past year, Denali Therapeutics Inc. (NASDAQ:DNLI) institutional owners must be relieved by the recent gain

Key Insights Given the large stake in the stock by institutions, Denali Therapeutics' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Using data from analyst forecasts alongside ow... Full story

Yahoo Finance • 2 years ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for... Full story

Yahoo Finance • 2 years ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkers Additional safety data up to... Full story

Yahoo Finance • 2 years ago

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

Interim results demonstrate average reduction of 64% (p <0.001) from baseline in serum NfL after 2 years of dosing with DNL310 in Phase 1/2 studyFDA has recommended assessment of NfL, a marker of neuroaxonal damage, as a possible biomarker... Full story

Yahoo Finance • 2 years ago

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship, Metaphore has built a first-in... Full story

Yahoo Finance • 2 years ago

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody... Full story

Yahoo Finance • 2 years ago

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)Clinical pharmacokinetic and ISR pharmacodynamic data, along with preclinical d... Full story

Yahoo Finance • 3 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for... Full story